Women’s health startup Mammogen has announced the closing of its $2M seed round. The round was oversubscribed by a diverse group of high-net-worth investors, comprising 52% women, members of the LGBTQ+ community, and veterans from the US Armed Forces, according to the company. “The vast diversity across our investor base is evidence that the world is ready for a truly differentiated women’s health narrative,”…
Daré Bioscience has announced positive topline results from its Phase 1 clinical trial of DARE-HRT1. DARE-HRT1 is a novel IVR designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period as part of a hormone therapy (HT) regimen to treat the vasomotor symptoms (VMS) and genitourinary syndrome associated with menopause. The topline data from the study support DARE-HRT1’s potential to…
Nutrafol, a leading hair wellness company, has launched a first-of-its-kind, physician-formulated nutraceutical supplement, Nutrafol Postpartum, that targets the root causes of hair thinning for women in the postpartum period. The newest addition to the company’s existing lineup of natural, clinically effective hair wellness supplements, Nutrafol Postpartum joins Nutrafol Women and Nutrafol Women’s Balance to support hair health through key stages of a…
Women’s health focused psychedelics startup Eastra Health has announced Emeline Maillet Ph.D. as Chief Scientific Officer. Dr. Maillet is a leading pharmacologist and neuroscientist with over twenty years of experience in academia and pharmaceuticals identifying and testing novel drug treatments for various conditions. Eastra Health is a biotech company dedicated to developing psychedelic-derived medicines designed for women. The company focuses on under-addressed…
Auransa, an artificial intelligence (AI) company developing precision medicines in areas of unmet medical needs, and Polaris Quantum Biotech (POLARISqb), a quantum drug design company, announced a research collaboration addressing therapeutics for neglected diseases disproportionately affecting women. The partnership seeks to discover treatments that may tackle many such diseases, and their complementary expertise promises to seek solutions that elude medical research. Auransa…
Aphrodite Health, a new biotech company in the rapidly emerging multibillion dollar psychedelic medicine sector, launches today. Founded by women, and focused on addressing women’s mental and physical health with psychedelic enhanced treatments, the company has developed a two pronged approach, with a long term drug discovery program to bring an FDA approved drug to market. Aphrodite Health is a US-based psychedelic…
Merck spin-off Organon today celebrates its launch as a global women’s health company with employees and women from around the world, as the Organon executive leadership team rings the opening bell at the New York Stock Exchange (NYSE). Recognizing the need to listen to and act on women’s experiences to address the challenges in women’s health, Organon gathered voices from around the…
Biotech company SCYNEXIS has announced FDA (U.S. Food and Drug Administration) approval of BREXAFEMME (ibrexafungerp tablets) for oral use in patients with vulvovaginal candidiasis (VVC), also known as vaginal yeast infection. BREXAFEMME is the first approved drug in a novel antifungal class in more than 20 years and was approved based on positive results from two Phase 3 studies in which oral ibrexafungerp demonstrated…
